210 Users Online
Blood Pressure Management Supplements Market by Ingredients (Mineral, Fibers, Vitamins, Omega-3 and Probiotics), Omega 3-based Blood Pressure Management Supplements Market is expected to grow at a CAGR of 4% from 2023 to 2033.
Newly-released Blood Pressure Management Supplements Market analysis report by Persistence Market Research reveals that global sales of Blood Pressure Management Supplements in 2022 were held at US$ 26.8 Billion. With a 4.1% projected CAGR from 2023 to 2033, the market is expected to reach a valuation of US$ 41.8 Billion by the end of the forecast period. Omega-3 ingredients are expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 4% from 2023 to 2033.
|
Attributes |
Details |
|
Global Blood Pressure Management Supplements Size (2023) |
US$ 28.1 Billion |
|
Global Blood Pressure Management Supplements Size (2033) |
US$ 41.8 Billion |
|
Global Blood Pressure Management Supplements CAGR (2023-2033) |
4.1% |
|
U.S Blood Pressure Management Supplements CAGR (2023 – 2033) |
2.9% |
|
Key Companies Covered |
|
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
As per the Blood Pressure Management Supplements research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2018 to 2022, the value of the Blood Pressure Management Supplements increased at around 5% CAGR. With an absolute dollar opportunity of US$ 13.7 Billion, the market is projected to reach a US$ 41.8 Billion valuation by 2033.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionThe increasing number of patients with high blood pressure is the prominent factor contributing to the expansion of the blood pressure management supplements market. One of the most controllable and preventable medical disorders is high blood pressure. However, between 50% and 80% of those who have high blood pressure do not take their medication as directed.
High blood pressure is a prominent contributor to strokes and heart attacks. It is a risk factor for vascular disease, kidney disease, and heart disease. An increase of 2mmHg of blood pressure is associated with a 10% increase in the risk of dying from a stroke and a 7% increase in the likelihood of dying from coronary heart disease.
According to American Heart Association (AHA), half of all adults in the United States have high blood pressure. Worldwide, hypertension is the leading cause of premature deaths accounting for around 10.8 million deaths in 2021.
According to World Health Organization, worldwide around 1.28 Million adults in the age group 30 to 79 have hypertension. Among these, two-thirds of the people belong to low and middle-income countries. But, around 46% of adults with hypertension are less likely to be aware of their condition. Thus, the reduction of hypertension prevalence by 33% between 2010 and 2030 is one of the global targets for non-communicable diseases. To achieve this goal there will be an increase in demand for blood pressure management supplements.
North America accounted for a market size of US$ 11.02 Billion in 2022 and is estimated to reach US$ 11.6 Billion by 2023. It is projected that North America will have a market worth US$ 17.2 Billion by 2033.
More than one in five people have hypertension, which is 22.7% of Canadian adults in the age group 20 years and above. The true prevalence of hypertension is higher as 17% of people with hypertension are unaware that they have it. In Canada, more than 21.1 Million general appointments were made to treat hypertension.
Every month doctors for antihypertensive medication give around 4 million prescriptions. Around 46% of women and 38% of men who are above 60 years are undergoing treatment for hypertension. Canada alone spends more than US$2.3 million every year on high blood pressure-related diseases. This is greatly impacting the blood pressure supplement market in North America.
Sales Team
Client Partner
United States Blood Pressure Management Supplements Market Analysis:
The market in the U.S. is expected to grow to be worth US$ 13.4 Billion with an absolute dollar growth of US$ 3.4 Billion till 2033. The Blood Pressure Management Supplements market in the United States has grown at a CAGR of 3.5% from 2018 to 2022 and is expected to grow at a CAGR of 2.9% from 2023 to 2033.
Hypertension was the key factor for more than 670,000 fatalities in the United States in 2020. Nearly 116 Million people have hypertension in the U.S. Among these, more than 37 Million U.S. adults have uncontrolled hypertension.
The United States spends about US$ 131 billion every year on the treatment of high blood pressure. The U.S. has seen an increase in the number of patients suffering from hypertension compared to previous years. This will play a significant role in the market expansion.
United Kingdom Blood Pressure Management Supplements Unit Market Analysis:
The market in the United Kingdom is expected to grow to be worth US$ 2.2 Billion with an absolute dollar growth of US$ 588 Million. The market in the country has grown at a CAGR of 3.8% from 2018 to 2022 and is expected to grow at a CAGR of 3.2% from 2023 to 2033.
High blood pressure is the third most common reason for all diseases after smoking and a poor diet in the U.K. Nearly, one-third of the U.K.’s population has high blood pressure. In England, around 31% of men and 28% of women have high blood pressure. According to the National Health Service, every year high blood pressure costs them more than £2.1 Million.
Around 12% of all general appointments account for patients with high blood pressure in England. Around £850 million of NHS would have been saved if the nation’s average systolic blood pressure is brought down by only 5mmHg. Thus, the government is trying to bring down this cost in the future by initiating new programs for creating awareness and treating hypertension. This will play a prominent role in the growth of the market.
China Blood Pressure Management Supplements Market Analysis:
The market in China is expected to grow to be worth US$ 3.6 Billion with an absolute dollar growth of US$ 1.4 Billion. The market in China has grown at a CAGR of 6.4% from 2018 to 2022 and is expected to grow at a CAGR of 5% from 2023 to 2033.
In China, around 270 Million people are suffering from hypertension. Out of which only 13.8% have their condition under control. But not all of them have access to therapy. In 2018, around 240 million adults in China in the age group of 18 and 69 had hypertension.
Of these, 164 million were unaware of their condition, and another 10 million were not receiving the right care. In 2019, more than 250 million people suffered from heart stroke whose main reason was high blood pressure. China has launched numerous national initiatives for the treatment and management of hypertension. Such initiatives by the government will positively affect the market.
Japan Blood Pressure Management Supplements Market Analysis:
The market in Japan is expected to grow to be worth US$ 3.1 Billion with an absolute dollar growth of US$ 891.9 Million. The market in Japan has grown at a CAGR of 4.2% from 2018 to 2022 and is expected to grow at a CAGR of 3.5% from 2023 to 2033.
In Japan, more than 43 million people are suffering from hypertension. Of these only, 50% of hypertensive persons are receiving treatment, and only around 25% have their blood pressure under control. Hypertension is one of the significant reasons for death in Japan. As of 2019, about 17% of adult women in Japan have hypertension, compared to about 23% of men.
The death rate from cardiovascular diseases in Japan is more than in the United States and Europe, as cardiovascular diseases are highly associated with hypertension. The main reason for the increasing number of patients with hypertension is the stressful work culture of Japan. This is the key factor that is contributing to the market growth in Japan.
Why the Market is for Omega 3-based Blood Pressure Management Supplements is projected to Witness the Fastest Growth?
The market for Omega 3-based Blood Pressure Management Supplements is projected to witness the fastest growth as it has grown at a CAGR of 4.8% from 2018 to 2022 and is expected to grow at a CAGR of 4% from 2023 to 2033.
Omega-3 is extensively used in the treatment of brain and heart-related diseases. Omega-3 is coming up as an alternative to Fish Oil. Numerous health advantages of omega-3 fatty acids have been demonstrated. They may in particular aid to boost heart and brain health, and offer protection from a number of chronic illnesses. Besides, several innovations are ongoing for the use of Omega-3. Thus, the various benefits of omega-3 are leading to its increasing demand in the market.
Through which distribution channel Blood Pressure Management Supplements Market is expected to Showcase Substantial Opportunity?
The market is projected to witness significant growth through hospital pharmacies as a distribution channel. The market through this channel has grown at a CAGR of 4.6% from 2018 to 2022 and is expected to grow at a CAGR of 3.9% from 2023 to 2033. Maintaining blood pressure in the appropriate range is a crucial part of any surgery.
Many times surgeries can be called out if the patient is having high or low blood pressure. Thus, during the course of surgery, the supply of blood pressure management supplements grows significantly which is mostly catered through hospital pharmacies. Due to this factor, hospital pharmacies play a significant role in the distribution of blood pressure supplements.
Key players in the Blood Pressure Management Supplements market are Pfizer Inc., Novartis International AG, Abbot Laboratories, Carlyle Group, Johnsons & Johnson, GlaxoSmithKline Plc., Amway, Bayer AG, Glanbia Nutritionals, and Herbalife International.
Some of the recent developments in the Blood Pressure Management Supplements market are:
By Ingredients
By Form
By Patient Type
By Distribution Channel
By Region
The market is estimated to be valued at US$ 28.1 Billion in 2023.
The market is expected to reach a US$ 41.8 Billion valuation of by 2033.
The market registered a CAGR of 5% over the last 4 years.
The market is projected to witness a CAGR of 4.1% from 2023 to 2033.
The market for Omega-3-based blood pressure management is expected to garner a significant value share by 2023.
Hospital pharmacies are expected a to garner significant value share by 2023.
The United States is projected to witness a market size of US$ 13.4 Billion by 2033 and is expected to grow at a 2.9% CAGR from 2023 to 2033.
Pfizer Inc., Novartis International AG, Abbot Laboratories, Carlyle Group, Johnsons & Johnson, GlaxoSmithKline Plc., Amway, Bayer AG, Glanbia Nutritionals, and Herbalife International are the key companies operating blood pressure management supplements market.
